89 -1 (29/1) 2020 — COMPARATIVE CHARACTERISTICS OF THE LIPID SPECTRUM IN CORONARY HEART DISEASE IN PATIENTS WITH AND WITHOUT OBESITY

COMPARATIVE CHARACTERISTICS OF THE LIPID SPECTRUM IN CORONARY HEART DISEASE IN PATIENTS WITH AND WITHOUT OBESITY

Raufov A.A., Bukhara State Medical institute.

Sulaymanova G.T., Bukhara State Medical institute.

Resume,

The study is based on a comparison of clinical and laboratory examination data of patients with coronary heart disease, obese and of normal body weight. We examined 97 patients aged 37-74 years (mean age 54.3 ± 2.5 years). Patients were divided into two groups: the first group consisted of 49 patients with abdominal obesity (BMI> 30.0; M ± m = 37.3 ± 0.4; OT> 94 cm; OT = 105.2 ± 3.0 cm ), the second group – 48 patients with normal body weight (BMI = 20.0 – 24.9; M ± m = 23.6 ± 0.4; FR <94; FR = 90.2 ± 2.0 cm) and overweight. Since patients with normal BMI and overweight prevailed in the second group of patients, and the results of their comparison were comparable, we considered it possible to combine them to create a control group.

Key words: obesity, coronary heart disease, lipid spectr, BMI, evaluating.

First page

324

Last page

328

For citation: Raufov A.A., Sulaymanova G.T.,Comparative characteristics of the lipid spectrum in coronary heart disease in patients with and without obesity//New Day in Medicine 1(29)2020 324-328 https://cutt.ly/RvNDaUf

List of References

  1. Бутрова, С. А. Метаболический синдром: патогенез, клиника, диагностика, лечение / С. А. Бутрова // Рус. мед. журн. – 2001. – Т. 9, № 2. – С. 10-36.
  2. Оганов, Р. Г. Развитие профилактической кардиологии в Рос­сии / Р. Г. Оганов, Г. Я. Масленникова // Кардиоваскуляр. те­рапия и профилактика. – 2004. -№ 3. – С. 11-14.
  3. Ройтберг Г.Е. Метаболический синдром / Г.Е. Ройтберг, А.В. Струтынский. – /М.: МЕДпресс, 2007. – 224 с.
  4. Бубнова М.Г. Ожирение: причины и механизмы нарастания массы тела, подходы к коррекции. /Бубнова М.Г. // Consilium medicum. 2005. – том 7. – № 5. – С.409-415.
  5. Бутрова С.А. Метаболический синдром: патогенез, клиника, диагностика, подходы к лечению. /Бутрова С.А. // Русский медицинский журнал. -2000. -том 2. -№9. С56-60.
  6. Маев И.В. и др. Биологически активные добавки к пище в профилактической и клинической медицине. /Маев И.В., Петухов А.Б., Тутельян В.А. и др. 7/-М.- 1999.
  7. Сторожаков Г.И. и др. Артериальная гипертензия и сопутству­ющие заболевания. /Сторожаков Г.И.., Шевченко О.П., Прас- курничий Е.А.// М. – Реафарм. – 2006. – С. 112.
  8. Aaron R.F., et al. Associations of general and abdominal obesity with multiple health outcomes in older women /Aaron R.F., Lawrence H.K. // Arch Inter Med. – 2000. – V0I.-I6O. – S.2117- 2128
  9.  Bouchard C. The biological predisposition to obesity: beyond the thrifty genotype scenario. /Bouchard C. // Int J Obes. – 2007. – 31. – P. 1337-1339.
  10. Lemieux I. et all. Hipertriglyceridemic waist. A marker of the atherogenic metabolic triad in men. / Lemieux I., Pascot A., Couillard C. et all. // Circulation.-2000. – Suppl 102. – S. 179-184
  11. Manson J.E. Obesity in the United States: a fresh look at its high toll. / Manson J.E., Bassuk S.S. // JAMA.- 2003. – 289. – P. 229­230.
  12. Sharma A.M. Ожирение и риск сердевдо-сосудистых забоёе- вании. Ожирение. /Sharma А.М. // Актуальные вопросы. – 2001. – № 5. – Р. 4-6.
  13. Hoffmann K. A German genome-wide linkage scan for type 2 diabetes supports the existence of a metabolic syndrome locus on chromosome lp36.13 and a type 2 diabetes locus on chromosome 16pl2.2. /Hoffmann K, Mattheisen M., Dahm S., et al. // Diabetologia. 2007. – Jul 50(7). – P. 141822.
  14. Lamba J.K. Genetic contribution to variable human CYP3A- mediated metabolism. / Lamba J.K., Lin Y.S., Schuetz E.G., et all. // Adv Drug Deliv Rev 2002; 54: 1271-94.
  15. G?mez-Abell?n P. Clock genes are implicated in the human metabolic syndrome. /G?mez-Abell?n P., Hern?ndez-Morante J.J., Luj?n J.A., Madrid J.A., Garaulet M.M. //Int J Obes (Lond). – 2008. – Jan 32(1) : P. 121-8.
  16. Lemieux I. Hipertriglyceridemic waist. A marker of the atherogenic metabolic triad in men. / Lemieux I., Pascot A., Couillard C. et all. // Circulation.-2000. – Suppl 102. – S. 179-184
  17. U.S. Department of health and human services // Public Health Service //National Institute ofHelth.-2001.S:3301-3305.
  18. Аметов А.С. Ожирение и сердечно-сосудистые забоёева^я. / Аметов А.С., Демидова Т.Ю., Цеёиковская A.JI. // Тер. Ар­хив.- 2001.- № 8.- С.69-72.
  19. Ferrannini E. Insulin: in search of a syndrome / E. Ferrannini, B. Balkau // Diabet. Medicine. – 2002. – Vol. 19, № 9. – P. 724-729.
  20. Ferrannini E. Metabolic syndrome: a solution in search of a problem / E. Ferrannini // J. Clinic. Endocrinology a. Metabolism. – 2007. – Vol. 92, № 2. – P. 396-398.

file

download